ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 233 filers reported holding ROYALTY PHARMA PLC in Q2 2021. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $111,158,519 | +18.7% | 4,095,745 | +34.4% | 6.01% | +19.9% |
Q2 2023 | $93,666,286 | -14.7% | 3,047,049 | 0.0% | 5.01% | +8.0% |
Q1 2023 | $109,785,175 | +40.7% | 3,047,049 | +54.3% | 4.64% | +41.5% |
Q4 2022 | $78,037,180 | +5.4% | 1,974,625 | +7.2% | 3.28% | +6.6% |
Q3 2022 | $74,040,000 | -42.8% | 1,842,718 | -40.1% | 3.07% | -37.5% |
Q2 2022 | $129,420,000 | +64.0% | 3,078,506 | +52.0% | 4.92% | +104.1% |
Q1 2022 | $78,918,000 | +0.7% | 2,025,610 | +3.0% | 2.41% | +58.8% |
Q4 2021 | $78,396,000 | +42.0% | 1,967,273 | +28.8% | 1.52% | +63.2% |
Q3 2021 | $55,218,000 | +84.7% | 1,527,900 | +109.5% | 0.93% | +108.1% |
Q2 2021 | $29,897,000 | -28.4% | 729,377 | -23.8% | 0.45% | -27.6% |
Q1 2021 | $41,747,000 | -76.5% | 957,053 | -73.1% | 0.62% | -75.7% |
Q4 2020 | $178,024,000 | +50.5% | 3,556,933 | +26.5% | 2.54% | +19.3% |
Q3 2020 | $118,317,000 | +13.2% | 2,812,381 | +30.6% | 2.13% | -5.1% |
Q2 2020 | $104,528,000 | – | 2,153,000 | – | 2.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |